BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. 1998

M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
Department of Pediatrics, Boston Medical Center, Massachusetts 02118, USA. markm@bu.edu

The safety, toxicity, and pharmacokinetics of intrapartum and early newborn nevirapine were evaluated in 17 human immunodeficiency virus type 1-infected women in labor and their newborns. No adverse effects of nevirapine were noted in any study mothers or infants. Following maternal dosing with 200 mg during labor, concentrations exceeding 100 ng/mL (10 times the in vitro IC50) were achieved in the newborns. Nevirapine elimination was prolonged in both mothers and infants, with median half-lives ranging from 36.8 to 65.7 h. Administration of 200 mg orally to the mothers in labor and of a single 2-mg/kg oral dose to the infants at 48-72 h after birth maintained serum concentrations in the infants > 100 ng/mL through 7 days of life.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011251 Pregnancy Complications, Infectious The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION. Complications, Infectious Pregnancy,Infectious Pregnancy Complications,Maternal Sepsis,Pregnancy, Infectious Complications,Sepsis during Pregnancy,Sepsis in Pregnancy,Infectious Pregnancy Complication,Pregnancy Complication, Infectious,Sepsis in Pregnancies,Sepsis, Maternal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study.
November 1999, The Journal of infectious diseases,
M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.
March 2009, Antimicrobial agents and chemotherapy,
M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
February 1997, The Journal of infectious diseases,
M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
January 2011, Antimicrobial agents and chemotherapy,
M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.
December 2004, The Journal of infectious diseases,
M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.
December 2000, The Journal of infectious diseases,
M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).
February 2000, The Journal of infectious diseases,
M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.
September 2003, Pediatrics,
M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
March 2001, The Journal of infectious diseases,
M Mirochnick, and T Fenton, and P Gagnier, and J Pav, and M Gwynne, and S Siminski, and R S Sperling, and K Beckerman, and E Jimenez, and R Yogev, and S A Spector, and J L Sullivan
The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076).
June 1999, The Journal of pediatrics,
Copied contents to your clipboard!